has decided to embark on the path of fine-tuning and developing rhNGF in its formulation for clinical use, at its own biotech facility in L’Aquila. and in Naples, where there are the laboratories of Drug Discovery and Technology Formulation, within a long-term collaboration with CNR. Italian excellence: the Dompé Hub in L’Aquila. Dompé has concentrated its manufacturing and research and development activities at its L’Aquila hub.
|Published (Last):||23 October 2008|
|PDF File Size:||7.33 Mb|
|ePub File Size:||8.82 Mb|
|Price:||Free* [*Free Regsitration Required]|
Provide answers to unresolved health-related questions in order to meet the needs of patients worldwide. To achieve the ambitious goal of providing answers to health questions, the continual pursuit of excellence and the ability to work as a system are, in fact, critical.
Clinical studies are therefore developed in cooperation with the above counterparts to ensure the highest level of safety to their participants, operating in full compliance with the scientific and ethical standards that govern clinical research and formulatjon the results of the research conducted with the scientific community, regulatory authorities and institutions.
This study is aimed at assessing the safety and the efficacy of two dose regimens of recombinant human nerve growth factor rhNGF eye drops solution compared to vehicle for inducing a complete healing of stage 2 persistent epithelial defect and 3 corneal ulcer neurotrophic keratitis. Click here to read more.
The safety of ladarixin in the specific clinical setting will be also evaluated. Click here to continue reading.
Reparixin oral tablets are being tested as a CSC targeting agent in patients with metastatic non- human epidermal growth factor receptor HER2 -amplified BC. The chemokine CXCL8 plays a key role in the recruitment and activation of polymorphonuclear neutrophils in post-ischemia reperfusion injury after organ transplantion.
Reparixin is the first low molecular weight blocker of CXCL8 biological activity in clinical development. An endeavour that starts out thanks to the research of Nobel Prize winner Rita Levi Montalcini, for the development and production of potential biotechnological drugs for the treatment of rare eye diseases. Click here to learn more. The fruit of its own research, these drugs are capable of acting on the inhibition of interleukin-8 IL-8a molecule responsible for both the pathogenesis of foemulation 1 diabetes and for the inflammatory reaction immediately following the transplantation of pancreatic islets, which limits the efficacy of this therapeutic approach, which is targeted to a group of patients with advanced-stage type-1 diabetes.
Discovered in the s by Forjulation Prize winner Rita Levi Montalcini, NGF belongs to the neurotrophins, a family of proteins that can play a crucial role in regulating the survival, development and functions of neurons, both at a central and peripheral level. NGF was the first neurotrophic factor to be identified and purified and over the last fifty years, its role in neuronal development and its biological activity on neural tissue formulatioj been of great interest to science.
The molecule is at an advanced stage of clinical development phase 3 in the field of therapeutic solutions to treat type 1 diabetes type as a way to improve the efficacy of pancreatic islet transplantation, whether autologous or allogeneic i. Reparixin is an inhibitor of CXCR1 and CXCR2 receptors activated by interleukin-8 IL-8a key chemotactic factor in the inflammatory reaction immediately following pancreatic islet dompd in patients with type 1 diabetes.
Our story | Dompé
Reparixin is the first of a new class of low-molecular-weight inhibitors that is selectively capable of modulating the activity of the receptor through an allosteric mechanism of action. Because of the significant innovation it introduces in the field and its potential to offer an effective response to the yet unmet need by reducing the risk of rejection in pancreatic islet transplantation an extremely rare conditionReparixin has been classified as an orphan drug by the FDA and EMA.
It acts as an inhibitor of IL-8, a molecule involved in the inflammatory processes leading to the progressive autoimmune destruction of the cells of the islets of Langerhans in type 1 diabetes.
Currently being tested in Phase II clinical trials, the drug is designed to counteract in an innovative way the inflammatory reactions that characterise the early stage of type 1 diabetes.
Career Paths | Dompé
Documents Discoveries from clinical studies.